TANABE KIYOSHI

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…